The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

PharMerica Corp

NYSE: PMC
Last

(U.S.) $32.35

Today's change+0.75 +2.37%
Updated May 22 4:02 PM EDT. Delayed by at least 15 minutes.
 

PharMerica Corp

NYSE: PMC
Last

(U.S.) $32.35

Today's change+0.75 +2.37%
Updated May 22 4:02 PM EDT. Delayed by at least 15 minutes.

PharMerica Corp Hits New 52-week High

PharMerica Corp closed up sharply Friday, rallying (U.S.)$0.75 or 2.37% to (U.S.)$32.35 and setting a new 52-week high. Over the last five days, shares have gained 8.74% and are currently 1.16% off of the 52-week high. Shares have outperformed the S&P 500 by 5.85% during the last year.

Key company metrics

  • Open(U.S.) $31.61
  • Previous close(U.S.) $31.60
  • High(U.S.) $32.73
  • Low(U.S.) $31.33
  • Bid / Ask-- / --
  • YTD % change+56.20%
  • Volume459,252
  • Average volume (10-day)424,271
  • Average volume (1-month)374,017
  • Average volume (3-month)358,833
  • 52-week range(U.S.) $19.42 to (U.S.) $32.73
  • Beta1.04
  • Trailing P/E87.47×
  • P/E 1 year forward19.91×
  • Forward PEG1.99×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.37
Updated May 22 4:02 PM EDT. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue512524470449
Total other revenue--------
Total revenue512524470449
Gross profit89948382
Total cost of revenue423429387367
Total operating expense495511457458
Selling / general / administrative59655658
Research & development--------
Depreciation / amortization7754
Interest expense (income), net operating--------
Unusual expense (income)610929
Other operating expenses, total--------
Operating income171313-10
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax151011-12
Income after tax1039-10
Income tax, total672-2
Net income1039-10
Total adjustments to net income--------
Net income before extra. items1039-10
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1039-10
Inc. avail. to common incl. extra. items1039-10
Diluted net income1039-10
Dilution adjustment0----0
Diluted weighted average shares31313130
Diluted EPS excluding extraordinary itemsvalue per share0.310.100.28-0.32
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share0.440.310.520.31